Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CC-671||CC671|CC 671||MPS1 Inhibitor 25||CC-671 inhibits CLK2 and TTK (MPS1), potentially resulting in decreased proliferation and increased apoptosis of tumor cells and reduced tumor growth (PMID: 29866747, PMID: 32478948).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||CC-671||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, CC-671 induced apoptosis and inhibited growth of triple-negative breast cancer (TNBC) cell lines in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft (PDX) models (PMID: 29866747).||29866747|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|